BRCA1 and metastatic prostate carcinoma: Prevalence of germline BRCA2 mutations with known pathogenic annotation was reported to be significantly higher in men with advanced and metastatic prostate cancer (3.1%) compared to organ-confined disease (0.7%) [45] Racial variation was also observed: African American patients carried more frequently BRCA1/2 variants of unknown significance (VUS) when compared to Caucasian Americans (4.6 vs. 1.6%, respectively).